Company Update (NYSE:MRK): Merck says hepatitis C treatment to lose "breakthrough" status

[Reuters] – Merck & Co on Wednesday said U.S. regulators intend to rescind the “breakthrough therapy” designation for its combination treatment for hepatitis C because other new drugs are available, a decision that . . . → Read More: Company Update (NYSE:MRK): Merck says hepatitis C treatment to lose "breakthrough" status Similar Articles: Stock Update (NYSE:AET): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount Company Update (NASDAQ:GILD): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment